Mendelian randomisation applied to drug development in cardiovascular disease: a review

Abstract excerpt

Despite increased expenditure, productivity of the pharmaceutical industry has decreased and currently 90% of developed molecules entering phase II and phase III clinical trials fail to gain regulatory approval. Most of these failures are due to lack of therapeutic efficacy rather than lack of safety, suggesting that drug development failures may often be due to poor drug target validation. Currently, drug...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Genetic Associations and Epidemiology
• Share to Lipoproteins and Cardiovascular Health
• Share to Statistical Methods in Clinical Trials